Spatiotemporal scaling changes in gait in a progressive model of Parkinson's disease.
Spatiotemporal scaling changes in gait in a progressive model of Parkinson's disease.
复制标题
DOI：
10.3389/fneur.2022.1041934
复制
发表时间：
2022
影响因子：
3.4
通讯作者：
中科院分区：
文献类型：
--
作者：
步态功能障碍是帕金森病 (PD) 患者最难治疗的运动症状之一。了解其病理生理学并开发针对帕金森步态功能障碍的更有效的治疗方法将需要临床前研究，以定量、客观地评估步态的空间和时间特征。我们开发了一种新的系统，用于测量非人类灵长类动物的意志、自然步态模式，然后应用该方法来表征帕金森步态功能障碍在一系列 1-甲基-4-苯基-1,2,3,6-四氢吡啶 (MPTP) 治疗中的进展，从而可以在轻度、中度和重度阶段进行受试者内比较。帕金森病步态功能障碍在不同治疗水平下的特点是步幅速度较慢、步幅周期的站立和摆动阶段时间增加以及步频降低，随着帕金森病的总体严重程度逐渐恶化。相比之下，步幅缩短在中度至重度帕金森病中最为明显。结果表明，灵长类帕金森病模型中的轻度帕金森病以时间步态缺陷开始，而空间步态缺陷在总体达到更严重的帕金森病状态后才显现。这项研究为非人类灵长类动物研究帕金森步态的神经生理学和治疗方法的临床前研究提供了重要的背景。
Gait dysfunction is one of the most difficult motor signs to treat in patients with Parkinson's disease (PD). Understanding its pathophysiology and developing more effective therapies for parkinsonian gait dysfunction will require preclinical studies that can quantitatively and objectively assess the spatial and temporal features of gait. We developed a novel system for measuring volitional, naturalistic gait patterns in non-human primates, and then applied the approach to characterize the progression of parkinsonian gait dysfunction across a sequence of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatments that allowed for intrasubject comparisons across mild, moderate, and severe stages. Parkinsonian gait dysfunction was characterized across treatment levels by a slower stride speed, increased time in both the stance and swing phase of the stride cycle, and decreased cadence that progressively worsened with overall parkinsonian severity. In contrast, decreased stride length occurred most notably in the moderate to severe parkinsonian state. The results suggest that mild parkinsonism in the primate model of PD starts with temporal gait deficits, whereas spatial gait deficits manifest after reaching a more severe parkinsonian state overall. This study provides important context for preclinical studies in non-human primates studying the neurophysiology of and treatments for parkinsonian gait.
登录
查看更多内容
影响因子：
3.7
作者：
Hass CJ;Malczak P;Nocera J;Stegemöller EL;Wagle Shukla A;Malaty I;Jacobson CE 4th;Okun MS;McFarland N
通讯作者：
McFarland N
影响因子：
4.6
作者：
Broom L;Ellison BA;Worley A;Wagenaar L;Sörberg E;Ashton C;Bennett DA;Buchman AS;Saper CB;Shih LC;Hausdorff JM;VanderHorst VG
通讯作者：
VanderHorst VG
影响因子：
3.4
作者：
Hausdorff, Jeffrey M.;Lowenthal, Justine;Giladi, Nir
通讯作者：
Giladi, Nir
影响因子：
4.4
作者：
BLIN, O;FERRANDEZ, AM;SERRATRICE, G
通讯作者：
SERRATRICE, G
影响因子：
2.4
作者：
Halliday, SE;Winter, DA;Prince, F
通讯作者：
Prince, F